Equities analysts forecast that Amedisys Inc (NASDAQ:AMED) will announce sales of $410.21 million for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Amedisys’ earnings. The lowest sales estimate is $399.50 million and the highest is $415.47 million. Amedisys posted sales of $380.16 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 7.9%. The business is expected to announce its next earnings report on Tuesday, November 6th.
According to Zacks, analysts expect that Amedisys will report full year sales of $1.65 billion for the current fiscal year, with estimates ranging from $1.64 billion to $1.65 billion. For the next year, analysts forecast that the business will post sales of $1.81 billion, with estimates ranging from $1.75 billion to $1.94 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Amedisys.
Amedisys (NASDAQ:AMED) last issued its earnings results on Tuesday, July 31st. The health services provider reported $1.00 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.22. The company had revenue of $411.60 million during the quarter, compared to analysts’ expectations of $403.62 million. Amedisys had a return on equity of 20.11% and a net margin of 4.46%. During the same period in the prior year, the business posted $0.62 EPS.
AMED has been the subject of several analyst reports. Royal Bank of Canada increased their target price on Amedisys to $115.00 and gave the company an “outperform” rating in a report on Friday, August 3rd. SunTrust Banks increased their target price on Amedisys to $130.00 and gave the company a “buy” rating in a report on Thursday. Cantor Fitzgerald initiated coverage on Amedisys in a report on Thursday, September 13th. They set a “neutral” rating and a $117.00 target price for the company. Robert W. Baird increased their target price on Amedisys from $105.00 to $120.00 and gave the company a “neutral” rating in a report on Thursday. Finally, Bank of America upgraded Amedisys from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $88.00 to $97.00 in a report on Tuesday, July 3rd. Five equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $95.38.
In other Amedisys news, insider David B. Pearce sold 398 shares of the stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $121.71, for a total value of $48,440.58. Following the completion of the sale, the insider now owns 11,818 shares in the company, valued at approximately $1,438,368.78. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 2.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. United Services Automobile Association lifted its holdings in Amedisys by 22.2% in the 2nd quarter. United Services Automobile Association now owns 5,182 shares of the health services provider’s stock worth $443,000 after buying an additional 942 shares during the period. Moody Aldrich Partners LLC bought a new position in shares of Amedisys in the 2nd quarter worth approximately $5,751,000. Advisors Asset Management Inc. bought a new position in shares of Amedisys in the 2nd quarter worth approximately $1,460,000. Glenmede Trust Co. NA raised its position in shares of Amedisys by 4.3% in the 2nd quarter. Glenmede Trust Co. NA now owns 71,559 shares of the health services provider’s stock worth $6,116,000 after acquiring an additional 2,959 shares in the last quarter. Finally, Moneta Group Investment Advisors LLC bought a new position in shares of Amedisys in the 2nd quarter worth approximately $181,000. Institutional investors and hedge funds own 93.31% of the company’s stock.
AMED stock traded down $4.21 during trading on Wednesday, hitting $109.28. 640,680 shares of the company traded hands, compared to its average volume of 312,146. The stock has a market capitalization of $3.98 billion, a PE ratio of 49.45, a P/E/G ratio of 1.89 and a beta of 1.00. Amedisys has a 1 year low of $45.60 and a 1 year high of $127.38. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.21 and a quick ratio of 1.21.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Further Reading: What Does Beta Mean In Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.